Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 6, 2006, Pages 1544-1548

  Clasby, Martin C ^a   Chackalamannil, Samuel ^a   Czarniecki, Michael ^a   Doller, Dario ^a   Eagen, Keith ^a   Greenlee, William J ^a   Lin, Yan ^a   Tsai, Hsingan ^a   Xia, Yan ^a   Ahn, Ho Sam ^a   Agans Fantuzzi, Jacqueline ^a   Boykow, George ^a   Chintala, Madhu ^a   Foster, Carolyn ^a   Bryant, Matthew ^a   Lau, Janice ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonist; PAR 1; Quinoline; Receptor; Thrombin

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN INHIBITOR; THROMBIN RECEPTOR; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; EX VIVO STUDY; MONKEY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD PLATELETS; FIBRINOLYTIC AGENTS; HETEROCYCLIC COMPOUNDS, 3-RING; MACACA FASCICULARIS; PLATELET AGGREGATION INHIBITORS; PYRIDINES; QUINOLINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32044441604     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.12.042     Document Type: Article

References (20)

1. Coleman, R. W.; Marder, V. J.; Salzman, E. W.; Hirsh, J. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 1994, pp 3-17.
2. E.W. Davie, K. Fujikawa, and W. Kisiel Biochemistry 30 1991 10363
3. S.R. Coughlin Proc. Natl. Acad. Sci. U.S.A. 96 1999 11023
4. S.R. Coughlin R.A. Bradshaw E.A. Dennis Handbook of Cell Signaling 1 2004 Elsevier San Diego, USA 167 171
5. Coughlin, S. R. Protease-Activated Receptors in the Cardiovascular System. Cold Spring Harb. Symp. Quant. Biol. 2002, 67, 197.
6. S.R. Coughlin Thromb. Haemost. 86 2001 298
7. R.J.A. Grand, A.S. Turnell, and P.W. Grabham J. Biochem. 313 1996 353
8. T.-K.H. Vu, D.T. Hung, V.I. Wheaton, and S.R. Coughlin Cell 64 1991 1057
9. S.R. Coughlin Proc Natl. Acad. Sci. U.S.A. 96 1999 11023
10. D.T. Hung, T.-H. Vu, N.A. Nelken, and S.R. Coughlin J. Cell Biol. 116 1992 827
11. T.-K.H. Vu, V.I. Wheaton, D.T. Hung, I. Charo, and S.R. Coughlin Nature 353 1991 674
12. T. Nanevicz, M. Ishii, L. Wang, M. Chen, J. Chen, C.W. Turck, F.E. Cohen, and S.R. Coughlin J. Biol. Chem. 270 1995 21619
13. S. Chackalamannil Curr. Opin. Drug Discov. Devel. 4 2001 417
14. S.M. Seiler, and M.S. Bernatowicz Curr. Med. Chem.-Cardiovasc. Hematol. Agents 1 2003 13
15. S. Chackalamannil, Y. Xia, W. Greenlee, M. Clasby, D. Doller, H. Tsai, T. Asberom, M. Czarniecki, H.-S. Ahn, G. Boykow, C. Foster, J. Agans-Fantuzzi, M. Bryant, J. Lau, and M. Chintala J. Med. Chem. 48 2005 5884
16. R. Tanikaga, Y. Nozaki, T. Tamura, and A. Kaji Synthesis 1983 134
17. P. Four, and F. Guibe J. Org. Chem. 46 1981 4439
18. 50 < 100 nM) were assayed multiple times (n ≥ 5, SD ± 20%). See Ref. 15 for modifications required for this class of compounds.
19. R.M. Williams, and E. Kwast Tetrahedron Lett. 30 1989 451
20. (0-4h) of 826 ng h/ml when dosed under similar conditions but did not show substantial activity in the ex vivo model of platelet aggregation.